Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.38 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10780071 | 0.87 | CDK5 (0.43) | CDK5CDK5R1NR1I3MBOAT4CYP19A1 | |
| SCHEMBL2955007 | 0.80 | CYP19A1 (0.59) | CDK5CDK5R1NR1I3MBOAT4CYP19A1 | |
| SCHEMBL5450814 | 0.80 | CYP19A1 (0.59) | CDK5CDK5R1NR1I3MBOAT4CYP19A1 | |
| SCHEMBL947526 | 0.79 | CDK5 (0.47) | CDK5CDK5R1NR1I3MBOAT4CYP19A1 | |
| SCHEMBL10609022 | 0.75 | CDK5 (0.44) | CDK5CDK5R1NR1I3MBOAT4CYP19A1 | |
| SCHEMBL10609234 | 0.74 | CDK5 (0.43) | CDK5CDK5R1NR1I3MBOAT4CYP19A1 | |
| SCHEMBL11654859 | 0.74 | NR1I3 (0.46) | CDK5CDK5R1NR1I3MBOAT4CYP19A1 | |
| SCHEMBL4617584 | 0.68 | CDK5 (0.47) | CDK5CDK5R1NR1I3MBOAT4CYP19A1 | |
| SCHEMBL11610130 | 0.68 | CDK5 (0.47) | CDK5CDK5R1NR1I3MBOAT4CYP19A1 | |
| SCHEMBL11537301 | 0.68 | CDK5 (0.47) | CDK5CDK5R1NR1I3MBOAT4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220054501-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR b (ER.beta) POSITIVE BREAST TUMOR | DCIC BIOPHARMACEUTICAL LIMITED (HK) | 2022-02-24 | — | — | US | disclosed |
| EP-3860611-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR SS (ERSS) POSITIVE BREAST TUMOR | dcic Biopharmaceutical Limited (HK) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020120739-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR ß (ERß) POSITIVE BREAST TUMOR | DCIC BIOPHARMACEUTICAL LIMITED (CN) | 2020-06-18 | — | — | WO | disclosed |
| EP-3666276-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR BETA (ERBETA) POSITIVE BREAST TUMOR | dcic Biopharmaceutical Limited (HK) | 2020-06-17 | — | — | EP | disclosed |
| US-9610292-B2 | Uses for 4,17β-dihydroxyandrost-4-ene-3-one | MABEL GMBH (DE) | 2017-04-04 | — | — | US | disclosed |
| EP-2556082-B1 | SUBSTITUTED ANDROST-4-ENE DIONES | UNIV EMORY (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20160030448-A1 | Uses for 4, 17ß-dihydroxyandrost-4-ene-3-one | MABEL GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| US-9138477-B2 | Uses for 4,17β-dihydroxyandrost-4-ene-3-one | MABEL GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-9114163-B2 | Medication against breast cancer and related diseases | MABEL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-20150148321-A1 | SUBSTITUTED ANDROST-4-ENE DIONES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-28 | — | — | US | disclosed |
| US-4840943-A | Androst-4-ene-3,17-diones and process for their preparation | FARMITALIA CARLO EBRA S.R.L. (IT) | 1989-06-20 | — | — | US | disclosed |
| US-4824830-A | AROMATASE INHIBITORS; ANTICARCINOGENIC AGENTS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-04-25 | — | — | US | disclosed |
| US-4822528-A | AROMATASE INHIBITORS; TREATMENT OF HORMONE-DEPENDENT TUMORS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-04-18 | — | — | US | disclosed |
| EP-0307135-A1 | 17-substituted androsta-1,4-dien-3-one derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1989-03-15 | — | — | EP | disclosed |
| US-4810423-A | AROMATASE INHIBITORS, ANTICANCER | FARMITALIA CARLO ERBA S. R. L. (IT) | 1989-03-07 | — | — | US | disclosed |
| US-4808616-A | 6-substituted androsta-1,4-diene-3,17-diones | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-02-28 | — | — | US | disclosed |
| US-4808578-A | ANTICARCINOGENIC AGENTS | FARMITALIA CARLO ERBA S. R. L. (IT) | 1989-02-28 | — | — | US | disclosed |
| EP-0265119-A1 | 1,2-Beta-methylene-4-substituted androstene-3,17-dione derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-04-27 | — | — | EP | disclosed |
| EP-0260975-A1 | 4-Substituted 6- alkylidenandrostene-3,17-dione derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-03-23 | — | — | EP | disclosed |
| EP-0250262-A1 | New androst-4-ene-3,17-diones and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1987-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148321-A1 | SUBSTITUTED ANDROST-4-ENE DIONES | HSD17B11, AR, NR5A1 | CDK5 288/4885CDK5R1 184/4885NR1I3 88/4885 |
| US-20220054501-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR b (ER.beta) POSITIVE BREAST TUMOR | ESR1, GPER1, CYP19A1 | CDK5 2432/4885CDK5R1 1257/4885NR1I3 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.